Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Dellinger, Ryan W ^a,b   Matundan, Harry H ^b   Ahmed, Amelia S ^b   Duong, Priscilla H ^b   Meyskens, Frank L ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAMETHICIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIRUBICIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B10; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GLUCURONIDATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; NEWBORN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DACARBAZINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCURONOSYLTRANSFERASE; HUMANS; INDOLES; MELANOCYTES; MELANOMA; SULFONAMIDES;

EID: 84867726406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047696     Document Type: Article

References (42)

1. Nagar S, Remmel RP, (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25: 1659-1672.
2. Tukey RH, Strassburg CP, (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40: 581-616.
3. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, et al. (2007) Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 28: 2412-2418.
4. Basu NK, Kovarova M, Garza A, Kubota S, Saha T, et al. (2005) Phosphorylation of a UDP-glucuronosyltransferase regulates substrate specificity. Proc Natl Acad Sci U S A 102: 6285-6290.
5. Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, et al. (2008) Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling. J Steroid Biochem Mol Biol 109: 247-253.
6. Starlard-Davenport A, Lyn-Cook B, Radominska-Pandya A, (2008) Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 73: 611-620.
7. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI, (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199: 354-363.
8. Giuliani L, Ciotti M, Stoppacciaro A, Pasquini A, Silvestri I, et al. (2005) UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13: 185-191.
9. King CD, Rios GR, Green MD, Tephly TR, (2000) UDP-glucuronosyltransferases. Curr Drug Metab 1: 143-161.
10. Zheng Z, Fang JL, Lazarus P, (2002) Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30: 397-403.
11. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P, (2006) Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34: 943-949.
12. Gray-Schopfer V, Wellbrock C, Marais R, (2007) Melanoma biology and new targeted therapy. Nature 445: 851-857.
13. Chin L, (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3: 559-570.
14. Meyskens FL Jr, Farmer PJ, Yang S, Anton-Culver H, (2007) New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res 174: 191-195.
15. Miller AJ, Mihm MC Jr, (2006) Melanoma. N Engl J Med 355: 51-65.
16. Ko JM, Fisher DE, (2011) A new era: melanoma genetics and therapeutics. J Pathol 223: 242-251.
17. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma NEJM. 363: 809-819.
18. Smalley KS, Sondak VK, (2010) Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 363: 876-878.
19. Eisinger M, Marko O, (1982) Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci U S A 79: 2018-2022.
20. Liu F, Fu Y, Meyskens FL Jr, (2009) MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J Invest Dermatol 129: 422-431.
21. Yang S, Meyskens FL Jr, (2005) Alterations in activating protein 1 composition correlate with phenotypic differentiation changes induced by resveratrol in human melanoma. Mol Pharmacol 67: 298-308.
22. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, et al. (2008) Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther 7: 3751-3760.
23. Yang S, Meyskens FL (2008) Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1) a unique target for the prevention and treatment of human melanoma. Antioxid Redox Signal.
24. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P, (2008) Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 18: 181-191.
25. Desai AA, Innocenti F, Ratain MJ, (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13: 517-523.
26. Lazard D, Zupko K, Poria Y, Nef P, Lazarovits J, et al. (1991) Odorant signal termination by olfactory UDP glucuronosyl transferase. Nature 349: 790-793.
27. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, et al. (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15: 502-510.
28. Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH, et al. (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82: 1-9.
29. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
30. Lal S, Mahajan A, Chen WN, Chowbay B, (2010) Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11: 115-128.
31. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ, (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29: 686-692.
32. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, et al. (2007) Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369: 498-511.
33. Zhang H, Patana AS, Mackenzie PI, Ikushiro SI, Goldman A, et al. (2012) Human UGT Expression in Insect Cells; the Ratio of Active to Inactive Recombinant Proteins and the Effects of a C-terminal His-tag on Glucuronidation Kinetics. Drug Metab Dispos.
34. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T, (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36: 1461-1464.
35. Buckley DB, Klaassen CD, (2009) Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. Drug Metab Dispos 37: 834-840.
36. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, et al. (2007) The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16: 823-828.
37. Saracino MR, Lampe JW, (2007) Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. Nutr Cancer 59: 121-141.
38. Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, et al. (2004) UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 24: 2893-2896.
39. Basseville A, Preisser L, de Carne Trecesson S, Boisdron-Celle M, Gamelin E, et al. (2011) Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer 10: 80.
40. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, et al. (2005) Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11: 8467-8475.
41. Ethell BT, Anderson GD, Burchell B, (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 65: 1441-1449.
42. Little AS, Smith PD, Cook SJ (2012) Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene.